IL99759A - Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them - Google Patents

Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL99759A
IL99759A IL99759A IL9975991A IL99759A IL 99759 A IL99759 A IL 99759A IL 99759 A IL99759 A IL 99759A IL 9975991 A IL9975991 A IL 9975991A IL 99759 A IL99759 A IL 99759A
Authority
IL
Israel
Prior art keywords
aminoindan
propargyl
mono
preparation
pharmaceutical compositions
Prior art date
Application number
IL99759A
Other languages
English (en)
Other versions
IL99759A0 (en
Inventor
Sterling Jeff
Levy Ruth
Veinberg Alex
Goldenberg Willy
Finberg John
Youdim Musa
Gutman Arieh
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL99759A priority Critical patent/IL99759A/xx
Priority to IL11281991A priority patent/IL112819A/en
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL99759A0 publication Critical patent/IL99759A0/xx
Priority to AU26063/92A priority patent/AU649565B2/en
Priority to ZA927570A priority patent/ZA927570B/xx
Priority to FI924458A priority patent/FI113262B/fi
Priority to NZ244616A priority patent/NZ244616A/en
Priority to CA002079968A priority patent/CA2079968C/en
Priority to HU9203162A priority patent/HU217589B/hu
Priority to CN92113070A priority patent/CN1038928C/zh
Priority to DK92402821.0T priority patent/DK0538134T3/da
Priority to EP92402821A priority patent/EP0538134B1/en
Priority to ES92402821T priority patent/ES2101063T3/es
Priority to DE69218101T priority patent/DE69218101T2/de
Priority to AT92402821T priority patent/ATE149999T1/de
Priority to JP27731492A priority patent/JP3247165B2/ja
Priority to US08/310,480 priority patent/US5486541A/en
Priority to GR970401207T priority patent/GR3023556T3/el
Publication of IL99759A publication Critical patent/IL99759A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL99759A 1991-10-16 1991-10-16 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them IL99759A (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IL99759A IL99759A (en) 1991-10-16 1991-10-16 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL11281991A IL112819A (en) 1991-10-16 1991-10-16 Fluorinated 1-aminoindan compounds and a process for their preparation
AU26063/92A AU649565B2 (en) 1991-10-16 1992-09-30 Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
ZA927570A ZA927570B (en) 1991-10-16 1992-10-01 Mono-fluorinated derivatives of N-propagyl-1-aminoindan and their use as inhibitors of monoamine oxidase.
FI924458A FI113262B (fi) 1991-10-16 1992-10-02 Menetelmä N-propargyyli-1-aminoindaanin fluorattujen johdannaisten valmistamiseksi
NZ244616A NZ244616A (en) 1991-10-16 1992-10-05 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, preparation and pharmaceutical compositions thereof
CA002079968A CA2079968C (en) 1991-10-16 1992-10-06 Mono-fluorinated derivatives of n-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
HU9203162A HU217589B (hu) 1991-10-16 1992-10-06 N-propargil-1-amino-indán monofluorszármazékai és ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek és a gyógyászati készítmények előállítására
CN92113070A CN1038928C (zh) 1991-10-16 1992-10-14 制备单氟化的n－炔丙基－1－氨基茚满衍生物的方法
DK92402821.0T DK0538134T3 (da) 1991-10-16 1992-10-15 Monofluorerede derivater af N-propargyl-1-aminoindan og deres anvendelse som inhibitorer for monoaminoxidase
JP27731492A JP3247165B2 (ja) 1991-10-16 1992-10-15 Ｎ−プロパルギル−１−アミノインダンのモノ−弗素化誘導体、これを有効成分とする薬剤およびその製造方法
EP92402821A EP0538134B1 (en) 1991-10-16 1992-10-15 Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
ES92402821T ES2101063T3 (es) 1991-10-16 1992-10-15 Derivados monofluorados de n-propargil-1-amino-indano y su utilizacion como inhibidores de la monoamin-oxidasa.
DE69218101T DE69218101T2 (de) 1991-10-16 1992-10-15 Monofluorierte Derivate von N-Propargyl-1-Aminoindan und deren Verwendung als Monoamino-Oxidaseinhibitoren
AT92402821T ATE149999T1 (de) 1991-10-16 1992-10-15 Monofluorierte derivate von n-propargyl-1- aminoindan und deren verwendung als monoamino- oxidaseinhibitoren
US08/310,480 US5486541A (en) 1991-10-16 1994-09-22 Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
GR970401207T GR3023556T3 (en) 1991-10-16 1997-05-26 Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL99759A IL99759A (en) 1991-10-16 1991-10-16 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL99759A0 IL99759A0 (en) 1992-08-18
IL99759A true IL99759A (en) 1997-06-10

Family

ID=11062970

Family Applications (2)

Application Number Title Priority Date Filing Date
IL11281991A IL112819A (en) 1991-10-16 1991-10-16 Fluorinated 1-aminoindan compounds and a process for their preparation
IL99759A IL99759A (en) 1991-10-16 1991-10-16 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL11281991A IL112819A (en) 1991-10-16 1991-10-16 Fluorinated 1-aminoindan compounds and a process for their preparation

Country Status (16)

Country Link
US (1) US5486541A (xx)
EP (1) EP0538134B1 (xx)
JP (1) JP3247165B2 (xx)
CN (1) CN1038928C (xx)
AT (1) ATE149999T1 (xx)
AU (1) AU649565B2 (xx)
CA (1) CA2079968C (xx)
DE (1) DE69218101T2 (xx)
DK (1) DK0538134T3 (xx)
ES (1) ES2101063T3 (xx)
FI (1) FI113262B (xx)
GR (1) GR3023556T3 (xx)
HU (1) HU217589B (xx)
IL (2) IL112819A (xx)
NZ (1) NZ244616A (xx)
ZA (1) ZA927570B (xx)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
AU7513494A (en) * 1993-08-06 1995-02-28 Upjohn Company, The 2-aminoindans as selective dopamine d3 ligands
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
DE69535315T2 (de) * 1994-01-10 2007-06-28 Teva Pharmaceutical Industries Ltd. 1-aminoindanderivate und zusammensetzungen hiervon
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
IL130528A (en) 1996-12-18 2004-12-15 Teva Pharma Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) * 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP1242066B1 (en) 1999-10-27 2006-06-28 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
ATE304522T1 (de) * 2000-05-04 2005-09-15 Warner Lambert Co Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US6956129B2 (en) 2001-02-16 2005-10-18 Bayer Aktiengesellschaft Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
AU2003290838A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US20080090915A1 (en) * 2003-11-25 2008-04-17 Technion Research And Development Foundation Ltd. Method for preventing or attenuating anthracycline-induced cardiotoxicity
WO2005051371A1 (en) 2003-11-25 2005-06-09 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
RU2404746C2 (ru) 2005-02-23 2010-11-27 Тева Фармасьютикал Индастриз, Лтд. Композиции разагилина с улучшенной однородностью содержимого
JP5253155B2 (ja) 2005-06-02 2013-07-31 ジェンリン ディスカバリー 肥満治療に有用なｍａｏ−ｂ阻害剤
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
WO2007061717A2 (en) 2005-11-17 2007-05-31 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
AU2006326642B2 (en) 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
CA2643235C (en) 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ZA200903903B (en) * 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
CN101600346B (zh) * 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
BRPI0905680A2 (pt) * 2008-01-11 2015-07-07 Teva Pharma "composição farmacêutica de uma composição farmacêutica"
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
EA201170018A1 (ru) * 2008-06-13 2011-08-30 Тева Фармасьютикал Индастриз, Лтд. Разагилин для изменения течения болезни паркинсона
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
EP2367782B1 (en) * 2008-12-22 2013-02-13 KRKA, D.D., Novo Mesto Process for preparation of ivabradine
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
WO2011003938A1 (en) 2009-07-09 2011-01-13 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
EP3517103A1 (en) 2010-02-03 2019-07-31 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
CA2851276A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
MX2014004201A (es) 2011-10-10 2015-01-12 Teva Pharma R(+)-n-metil-propargil-aminoindano.
TW201412304A (zh) 2012-08-17 2014-04-01 Teva Pharma 瑞沙吉林之非經腸調配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB1033686A (en) * 1965-05-10 1966-06-22 Maximilian Heller Improvements in convertible double bed settees
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IL99759A0 (en) 1992-08-18
ES2101063T3 (es) 1997-07-01
US5486541A (en) 1996-01-23
CA2079968C (en) 2004-12-21
DE69218101D1 (de) 1997-04-17
FI113262B (fi) 2004-03-31
HU9203162D0 (en) 1992-12-28
EP0538134A2 (en) 1993-04-21
HUT67218A (en) 1995-03-28
DE69218101T2 (de) 1997-09-25
ATE149999T1 (de) 1997-03-15
HU217589B (hu) 2000-02-28
IL112819A (en) 2001-11-25
CN1038928C (zh) 1998-07-01
GR3023556T3 (en) 1997-08-29
AU2606392A (en) 1993-04-22
DK0538134T3 (da) 1997-04-01
AU649565B2 (en) 1994-05-26
NZ244616A (en) 1995-04-27
FI924458A0 (fi) 1992-10-02
EP0538134A3 (en) 1993-06-16
FI924458A (fi) 1993-04-17
JPH05262701A (ja) 1993-10-12
EP0538134B1 (en) 1997-03-12
ZA927570B (en) 1993-04-14
CN1073427A (zh) 1993-06-23
CA2079968A1 (en) 1993-04-17
JP3247165B2 (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
IL99759A (en) Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
CA2092794A1 (fr) Naphtylalkylamines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69705300T2 (de) Cyclopropylalkansäurederivate
AU1608692A (en) Amidinophenylalanine derivatives, a process for the preparation thereof, use thereof and agents containing these as anticoagulants
AU673893B2 (en) New pyridothiadiazones, processes for their preparation and the pharmaceutical compositions which contain them
IL112622A0 (en) Camptothecin derivatives, their preparation and pharmaceutical compositions containing them
HRP940458B1 (en) New bis-naphtalimides for the treatment of canser
TW252979B (xx)
AU3559793A (en) New 3-aminochroman spiro compounds, processes for their preparation and pharmaceutical compositions containing them
HK1023346A1 (en) Novel substituted tetrahyropyridine derivatives, method of preparation and pharmaceutical compositions containing them
GR3017348T3 (en) Novel isoindolinone derivative, preparation thereof, and pharmaceutical compositions containing same.
AU654300B2 (en) 7-acyl-3-(substituted carbamoyloxy)cephem compounds and process for their preparation
IL100955A (en) Amino-polyhydroxy- cyclopentane derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
AU6970394A (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
ES2049186A1 (es) Procedimiento para la preparacion de nuevos derivados de benzofuranil-imidazol.
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
ES2027507A6 (es) Procedimiento de preparacion de derivados selenofenicos.
AU4965593A (en) Ureido-acetamide derivatives, preparation thereof and drugs containing same
AU659738B2 (en) New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees